Notizie AIOM – anno XV n. 652

21 Novembre 2017

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS. This study aimed ...
Leggi tutto

21 Novembre 2017

Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial – PRODIGE 20 study results

Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance ...
Leggi tutto

21 Novembre 2017

17 novembre 2017 – Domani Giornata Europea della Consapevolezza sugli Antibiotici. Le iniziative AIFA

17 Novembre 2017

17 novembre 2017 – Determinazioni AIFA n° 1821-1822 del 31/11//2017

17 Novembre 2017

15 novembre 2017 – Liste di Trasparenza

17 Novembre 2017

FDA Approves Fulvestrant in Combination With Abemaciclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

November 15, 2017 - Today, the U.S. Food and Drug Administration (FDA) approved a new indication for fulvestrant, expanding the drug's approved use to include combined therapy with abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, for the treatment of hormone receptor–positive, ...
Leggi tutto

17 Novembre 2017

FDA expands approval of Sunitinib to reduce the risk of kidney cancer returning

November 16, 2017 - The U.S. Food and Drug Administration today approved Sunitinib malate for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy). Adjuvant treatment ...
Leggi tutto

17 Novembre 2017

Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study

Our aim was to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs between those who receive androgen-deprivation therapy by surgical castration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy. By using the ...
Leggi tutto

17 Novembre 2017

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based ...
Leggi tutto

17 Novembre 2017

FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma

November 16, 2017 - The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according to Celgene Corporation and bluebird bio, the companies developing the anti–B-cell maturation antigen ...
Leggi tutto

LAVORIAMO CON

News

FOSSC: “BENE FINALMENTE L’ARRIVO DEI NUOVI LIVELLI ESSENZIALI D’ASSISTENZA DOPO BEN 9 ANNI DI ATTESA MA ORA SERVE CON RAPIDITA’ UN ULTERIORE AGGIORNAMENTO PER COPRIRE GLI ULTIMI 3 ANNI DI ACQUISIZIONE DI TRATTAMENTI INNOVATIVI”

MIASTENIA GRAVIS: IN ITALIA COLPITI PIU’ DI 15MILA UOMINI E DONNE. GLI ESPERTI, “PRIORITA’ LA PERSONALIZZAZIONE DELLE TERAPIE”

ITALFARMACO E JCR PHARMACEUTICALS STIPULANO UN ACCORDO DI LICENZA ESCLUSIVA PER LO SVILUPPO E LA POTENZIALE COMMERCIALIZZAZIONE DI UNA NUOVA TERAPIA SPERIMENTALE PER LA SINDROME DI HUNTER NEGLI STATI UNITI, EUROPA E AMERICA LATINA

GRUPPO FS E FONDAZIONE INCONTRADONNA: TORNA FRECCIAROSA, LA PREVENZIONE VIAGGIA IN TRENO

TUMORI UROLOGICI, IN ITALIA 87MILA NUOVE DIAGNOSI L’ANNO. LA SIUrO: “MALATTIE ETEROGENEE, NECESSARIE CURE PERSONALIZZATE”

TUMORE DEL SENO, INFORMAZIONI SODDISFACENTI SOLO PER 4 DONNE SU 10. EUROPA DONNA ITALIA: “MIGLIORARE LA COMUNICAZIONE MEDICO-PAZIENTE”

RICERCA: I PREMI TALES A SEI GIOVANI RICERCATRICI LOMBARDE. “NELLE IMMAGINI DI LABORATORIO LA BELLEZZA DELLA SCIENZA”

Notizie AIOM – anno XV n. 652

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial – PRODIGE 20 study results

17 novembre 2017 – Domani Giornata Europea della Consapevolezza sugli Antibiotici. Le iniziative AIFA

17 novembre 2017 – Determinazioni AIFA n° 1821-1822 del 31/11//2017

15 novembre 2017 – Liste di Trasparenza

FDA Approves Fulvestrant in Combination With Abemaciclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

FDA expands approval of Sunitinib to reduce the risk of kidney cancer returning

Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial

FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma